About NuCana plc - American Depositary Shares (NCNA)
Nucana Plc is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. The company utilizes its proprietary nucleoside chemistry platform to design and create next-generation nucleoside analogs that target various cancer types. Nucana aims to address the limitations of existing cancer therapies by developing treatments that can enhance efficacy and reduce toxicity, ultimately improving patient outcomes. Through its research and clinical trials, the company is dedicated to advancing new medicines that offer hope to patients battling challenging malignancies. Read More
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
EDINBURGH, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company that focuses on significantly improving treatment outcomes for patients with cancer, announced that it has priced a registered direct offering consisting of 10,845,985 American Depository Shares, or ADSs, (or pre-funded warrants in lieu thereof) with each ADS (or pre-funded warrant) accompanied by (i) a Series A warrant to purchase one (1) ADS at an initial exercise price of $0.8068 per share and (ii) a Series B Warrant to purchase one (1) ADS at an initial exercise price of $1.61 per share. The combined public offering price of each ADS together with the accompanying Series A and Series B Warrants is $0.6454, and the combined offering price of each pre-funded warrant together with the accompanying Series A and Series B warrants is $0.6454, minus the United States dollar equivalent of £0.01, based on the exchange rate on the date of pricing. The gross proceeds of the offering are expected to be approximately $7 million before deducting placement agent fees and offering expenses and are expected to be used to fund activities relating to the advancement of our drug discovery and development programs, and for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should we choose to pursue any, and collaborations. The closing of the offering is expected to occur on or about May 7, 2025, subject to the satisfaction of customary closing conditions.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
In today’s market, investors are scanning for deeply undervalued stocks with disruptive technology, breakthrough clinical assets, and high-impact news catalysts. Several oversold equities trading under $1 have emerged with notable developments, drawing algorithmic attention across trading platforms, financial news networks, and Google-indexed search results.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
